Stay updated on Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0; the study record is still inaccessible on the page.
    Difference
    0.2%
    Check dated 2026-11-03T23:32:05.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    An NIH-wide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the error page. The site revision advances from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T23:23:36.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The error page’s revision identifier changed from v3.7.0 to v3.7.1, while it continues to display a 403 Forbidden response.
    Difference
    0.2%
    Check dated 2026-10-07T00:34:28.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error page with a minimal header and a Home link, replacing the previous detailed study information and documents. This blocks access to the study record and its associated materials.
    Difference
    22%
    Check dated 2026-09-23T00:32:36.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.6 to v3.7.0, signaling a new build of the Study Details page rather than a change to the study information.
    Difference
    0.0%
    Check dated 2026-09-15T23:44:49.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The page's revision identifier was updated to v3.6.6, indicating a minor maintenance release of the page framework or content management system rather than substantive study changes.
    Difference
    0.0%
    Check dated 2026-09-01T19:44:19.000Z thumbnail image

Stay in the know with updates to Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial page.